Harel Insurance Investments & Financial Services Ltd. Has $575,000 Position in Edwards Lifesciences Corporation $EW

Harel Insurance Investments & Financial Services Ltd. increased its stake in Edwards Lifesciences Corporation (NYSE:EW) by 33.8% in the 2nd quarter, Holdings Channel reports. The firm owned 7,353 shares of the medical research company’s stock after purchasing an additional 1,859 shares during the period. Harel Insurance Investments & Financial Services Ltd.’s holdings in Edwards Lifesciences were worth $575,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Brighton Jones LLC acquired a new stake in shares of Edwards Lifesciences in the fourth quarter worth $266,000. Allspring Global Investments Holdings LLC lifted its stake in shares of Edwards Lifesciences by 0.5% in the first quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company’s stock worth $2,170,000 after buying an additional 145 shares during the last quarter. Rossby Financial LCC acquired a new stake in shares of Edwards Lifesciences in the first quarter worth $29,000. Private Trust Co. NA lifted its stake in shares of Edwards Lifesciences by 15.3% in the first quarter. Private Trust Co. NA now owns 3,966 shares of the medical research company’s stock worth $287,000 after buying an additional 525 shares during the last quarter. Finally, Teacher Retirement System of Texas lifted its stake in shares of Edwards Lifesciences by 196.5% in the first quarter. Teacher Retirement System of Texas now owns 105,358 shares of the medical research company’s stock worth $7,636,000 after buying an additional 69,825 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

EW has been the subject of a number of analyst reports. Truist Financial boosted their price objective on shares of Edwards Lifesciences from $82.00 to $87.00 and gave the stock a “hold” rating in a research note on Tuesday, October 28th. Citigroup upped their price target on Edwards Lifesciences from $95.00 to $96.00 and gave the stock a “buy” rating in a report on Friday. Morgan Stanley upped their price target on Edwards Lifesciences from $75.00 to $81.00 and gave the stock an “equal weight” rating in a report on Tuesday, July 15th. Mizuho upped their price target on Edwards Lifesciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a report on Friday. Finally, Raymond James Financial upgraded Edwards Lifesciences from a “market perform” rating to an “outperform” rating in a report on Monday. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Edwards Lifesciences presently has an average rating of “Moderate Buy” and a consensus target price of $91.00.

Edwards Lifesciences Stock Performance

EW opened at $82.48 on Monday. The stock has a market cap of $48.42 billion, a PE ratio of 11.87, a P/E/G ratio of 3.97 and a beta of 1.05. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06. The stock’s 50 day simple moving average is $77.58 and its 200-day simple moving average is $76.97. Edwards Lifesciences Corporation has a 1 year low of $64.89 and a 1 year high of $87.09.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.59 by $0.08. The firm had revenue of $1.55 billion for the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The business’s revenue for the quarter was up 14.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.67 EPS. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. Sell-side analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, insider Larry L. Wood sold 8,950 shares of the business’s stock in a transaction on Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the sale, the insider owned 206,900 shares of the company’s stock, valued at $16,150,614. The trade was a 4.15% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 1.29% of the stock is owned by company insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.